Medicxi Ventures Management (Jersey) Ltd has disclosed its holdings in a recent filing, providing insights into its investment strategy as of September 30, 2026. This report is significant as it showcases the firm’s commitment to the biotechnology sector, which is experiencing rapid growth and innovation.

Medicxi Ventures Management, incorporated in Jersey, focuses on investments in healthcare and biotechnology. The firm operates as a venture capital entity, supporting companies that aim to develop groundbreaking medical solutions. Its recent filing, dated November 2, 2026, is part of its regular reporting obligations under the SEC regulations.

According to the filing, Medicxi's total reported value of holdings amounts to approximately $126.7 million. The firm has made substantial investments in several biotech companies, including:

Aura Biosciences Inc., with a reported value of $19,090,522 and 3,039,892 shares.

NewAmsterdam Pharma Company, valued at $53,074,484 with 2,182,339 shares.

Phathom Pharmaceuticals Inc., holding a value of $54,491,376 and 7,464,572 shares.

These investments indicate Medicxi's strategy to capitalize on the growing demand for innovative therapies and treatments in the healthcare sector. The firm holds sole investment discretion over these shares, reflecting its confidence in the companies' potential for growth.

The filing may affect various stakeholders, including the companies Medicxi has invested in, as well as competitors within the biotechnology industry. The significant capital allocation by Medicxi could signal to the market a strong belief in the future performance of these biotech firms.

Looking ahead, it remains to be seen how these investments will perform in the evolving landscape of biotechnology. The filing does not specify any immediate next steps or actions from Medicxi Ventures Management.